申请人:Glaxo Laboratories Limited
公开号:US04074047A1
公开(公告)日:1978-02-14
Cephalosporin antibiotics in which the 7.beta.-acylamido group has the structure ##STR1## (WHERE R is phenyl, thienyl or furyl; R.sup.a and R.sup.b are each selected from hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.3-7 cycloalkyl, phenyl, naphthyl, thienyl, furyl, carboxy, C.sub.2-5 alkoxycarbonyl, aminocarbonyl, N-substituted aminocarbonyl and cyano, or R.sup.a and R.sup.b together with the carbon atom to which they are attached form a C.sub.3-7 cycloalkylidene or cycloalkenylidene group; R.sup.c is hydrogen or C.sub.1-4 alkyl; and m and n are each 0 or 1 such that the sum of m and n is 0 or 1) exhibit broad spectrum antibiotic activity characterized by particularly high activity against gram negative microorganisms, including those which produce .beta.-lactamases. The compounds, which are syn isomers or exist as mixtures of syn and anti isomers containing at least 90% of the syn isomer, have particularly good activity against Proteus organisms including indole positive strains and, especially when both R.sup.a and R.sup.b are other than hydrogen, against Pseudomonas organisms.
具有以下结构的头孢菌素抗生素,其中7.beta.-acylamido基团的结构为##STR1##(其中R为苯基,噻吩基或呋喃基; R.sup.a和R.sup.b分别选自氢,C.sub.1-4烷基,C.sub.2-4烯基,C.sub.3-7环烷基,苯基,萘基,噻吩基,呋喃基,羧基,C.sub.2-5烷氧基羰基,氨基羰基,N-取代氨基羰基和氰基,或R.sup.a和R.sup.b与它们所连接的碳原子一起形成C.sub.3-7环烷基亚甲基或环烯基亚甲基基团; R.sup.c为氢或C.sub.1-4烷基; m和n各为0或1,使m和n的和为0或1),表现出广谱抗生素活性,特别是对革兰氏阴性微生物具有极高的活性,包括产生β-内酰胺酶的微生物。这些化合物是syn异构体或存在于syn和anti异构体的混合物中,其中至少90%为syn异构体,对包括吲哚阳性菌株在内的变形杆菌具有特别好的活性,尤其是当R.sup.a和R.sup.b都不是氢时,对假单胞菌具有特别好的活性。